1. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
- Author
-
Anthony M. Joshua, Eshetu G. Atenafu, Poulam M. Patel, L. de Vries, Sophie Piperno-Neumann, Serge Leyvraz, Nicolas Penel, Stefan Suciu, Leila Khoja, Sandip Pravin Patel, P. Huppert, G. Fiorentini, Ulrich Keilholz, Ernie Marshall, L. B. J. Van Iersel, Claudia Pfoehler, Lisa Zimmer, Takami Sato, Ahmad A. Tarhini, T. Vogl, Shailender Bhatia, Richard D. Carvajal, Tina Cheng, Tero Kivelä, Josep M. Piulats, Frédéric Mouriaux, Cambridge University Hospitals - NHS (CUH), University of Cambridge [UK] (CAM), Institut Curie [Paris], Nutrition, Métabolismes et Cancer (NuMeCan), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CHU Pontchaillou [Rennes], Princess Margaret Hospital, University of Toronto, Institut National de la Recherche Agronomique (INRA)-Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), HUS Head and Neck Center, Department of Ophthalmology and Otorhinolaryngology, Silmäklinikka, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Medische Oncologie (9)
- Subjects
Male ,Uveal Neoplasms ,0301 basic medicine ,Oncology ,Time Factors ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Medizin ,Datasets as Topic ,Phases of clinical research ,CHOROIDAL MELANOMA ,Kaplan-Meier Estimate ,Metastasis ,0302 clinical medicine ,STAGE-IV MELANOMA ,Prospective Studies ,Prospective cohort study ,Melanoma ,Aged, 80 and over ,Clinical Trials as Topic ,survival benchmarks ,Liver Neoplasms ,TEMOZOLOMIDE ,Hematology ,Middle Aged ,Prognosis ,Progression-Free Survival ,3. Good health ,Benchmarking ,Research Design ,030220 oncology & carcinogenesis ,CHEMOEMBOLIZATION TACE ,Female ,medicine.symptom ,uveal melanoma ,PHASE-II TRIAL ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,3122 Cancers ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,LIVER METASTASES ,Young Adult ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Sex Factors ,Metàstasi ,Internal medicine ,medicine ,Humans ,3125 Otorhinolaryngology, ophthalmology ,Progression-free survival ,[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs ,COMBINATION ,Aged ,Temozolomide ,L-Lactate Dehydrogenase ,business.industry ,Cancer ,Alkaline Phosphatase ,medicine.disease ,Elevated alkaline phosphatase ,meta-analysis ,1ST-LINE TREATMENT ,030104 developmental biology ,trial design ,INTRAARTERIAL ,business ,GEMCITABINE PLUS TREOSULFAN - Abstract
International audience; BACKGROUND: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.METHODS: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.RESULTS: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus
- Published
- 2019